Table 1.

In vitro and in vivo properties of DsbB mutants

Values represent the average of at least two independent experiments ± S.E. or the 95% confidence intervals in parentheses.

Mutant	kcata		Kmb		kcat/Km		IC50 of compound 12
	Ubiquinone	Menadione	Ubiquinone	Menadione	Ubiquinone	Menadione	In vitroc	In vivod
			μm				μm
DsbBWT	2.8 ± 0.07	1.9 ± 0.05	0.94 ± 0.1	35.8 ± 2.8	2.99	5.3 × 10−2	0.033 (0.029–0.039)	1.14 (1.09–1.18)
DsbBL25P	2 ± 0.03	0.54 ± 0.05	2.3 ± 0.1	174 ± 25	0.88	0.31 × 10−2	0.173 (0.157–0.192)	4.06 (3.84–5.52)
DsbBA29V	3 ± 0.2	1.4 ± 0.05	10.8 ± 1.5	90.5 ± 6.5	0.28	1.5 × 10−2	1.697 (1.54–1.79)	1.47 (1.39–1.56)
DsbBK39E	5.5 ± 0.2	0.8 ± 0.1	3 ± 0.4	201 ± 38	1.81	0.39 × 10−2	0.071 (0.065–0.079)	3.01 (2.75–3.30)
DsbBP100S	2.1 ± 0.06	0.66 ± 0.03	3.6 ± 0.4	47 ± 5.1	0.58	1.4 × 10−2	0.033 (0.030–0.037)	2.01 (1.93–2.1)
DsbBF106L	6.2 ± 0.09	0.69 ± 0.08	3.6 ± 0.2	61.8 ± 15	1.73	1.1 × 10−2	0.055 (0.049–0.063)	1.2 (1.05–1.37)

^a k_cat expressed as nanomoles of ubiquinone-1 or menadione per nmol of DsbB per s.

^b K_m values represent ubiquinone-1 or menadione concentrations.

^c In vitro inhibition was measured using 10 nm DsbB, 10 μm ubiquinone-1, and 20 μm reduced DsbA.

^d In vivo inhibition was measured by growth inhibition of strain lptD₄₂₁₃ΔdsbB dsbB_Ptrc204 (CL409–410, CL416–417, and LI18–19 strains) in the presence of drugs.